1 gh rate of chemoresistant recurrence and low
five-year survival rate.
2 Patients in this subgroup had the highest
five-year survival rate.
3 an aggressive neuroendocrine tumor with low
five-year survival rates.
4 confidence interval, 0.60 to 0.93; P=0.009;
five-year survival rate,
36 percent vs. 23 percent) and
5 The expected
five-year survival rate (
79 percent) was identical to th
6 Five-year survival rate after initiation of maintenance
7 One-year and
five-year survival rates after transplantation among pat
8 The
five-year survival rate among patients whose cancer had
9 A) is a rare biliary tract cancer with a low
five-year survival rate and high recurrence rate after s
10 Five-year survival rates approach 70% with surgical rese
11 Five-year survival rates are below 12%, even with the mo
12 Five-year survival rates are lowest for AYA women, and o
13 Five-year survival rates exceed 80% for the 45,000 child
14 The
five-year survival rate for ovarian cancer patients rema
15 The
five-year survival rate for patients diagnosed with adva
16 The current
five-year survival rate for systemic AL amyloidosis or m
17 Five-year survival rates for breast cancer as influenced
18 Although
five-year survival rates for childhood acute lymphoblast
19 Five-year survival rates for childhood cancer have impro
20 Five-year survival rates for early stage colorectal, bre
21 our understanding of neuroblastoma biology,
five-year survival rates for high-risk disease remain le
22 Five-year survival rates for patients with tumors less t
23 Five-year survival rates for resected intrahepatic, peri
24 Five-year survival rates for TM + and TM- were 21% and 7
25 ew cases of cancer worldwide in 2020 and the
five year survival rate growing from 50% in 1970 to 67%
26 Five-year survival rates have increased in the recent pa
27 myeloid leukemia (AML) patients have a poor
five-year survival rate highlighting the need for the id
28 Finally, we compared
five-year survival rates in blacks and whites.
29 Five-year survival rates increased from 83.7% in 1990-19
30 The
five-year survival rate is 45-48% because of the high fr
31 reatic cancer are suboptimal, resulting in a
five year survival rate of about 9%.
32 and non-small cell lung cancer (NSCLC) has a
five year survival rate of only 24%.
33 The
five-year survival rate of epithelial ovarian cancer (EO
34 nd limited screening methods, resulting in a
five-year survival rate of less than 10%.
35 all forms of cancer treatment and carries a
five-year survival rate of only 8%(1).
36 Five-year survival rate of OvCa ranges from 30-92%, depe
37 at early stage can significantly improve the
five-year survival rate of patients.
38 Five-year survival rate of stage IV patient with all of
39 Despite a
five-year survival rate of ~70%, nearly all patients inc
40 he chemotherapy resulted in overall two- and
five-year survival rates of 44 percent and 23 percent, a
41 Five-year survival rates of patients with VWF:Ag < 110,
42 The prognosis is poor and the
five-year survival rate ranges from 20% (OSCC in the flo
43 regurgitant orifice of at least 40 mm2 had a
five-year survival rate that was lower than expected on
44 Five-year survival rates typically range from 89% to 96%
45 e II disease whose tumors expressed DCC, the
five-year survival rate was 94.3 percent, whereas in pat
46 percent vs. 76.7 percent, P<0.001), and the
five-year survival rate was also lower for blacks (26.4
47 Five-year survival rates were 42% for patients receiving
48 Five-year survival rates were 72% (95% CI, 67-76) with i
49 Five-year survival rates were 86.5%, 83.8%, and 80.1% fo
50 Five-year survival rates were above 90% for patients wit
51 Five-year survival rates were excellent: 93.3% (95% CI,